3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
9
Neoplasm Metastasis
7
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Tongue Neoplasms
1
Thymoma
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Neoplasms
1
Hypoxia
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Gliosarcoma
1
Interventions
NVP-BKM120
1
Bacterial Load
1
3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hypoxia
×
NVP-BKM120
×
Clear all
NCT02128724
2019-08-01
BKM120
University of Oxford
Phase 1
Completed
21 enrolled
23 charts